and we for Jenna, a stage fully joining from been for purely thanks year as company TG, a has you, integrated good everybody, pivotal transitioned into us. development Thank organization. morning, commercial and a XXXX
UX commercial course, believe the and this leverage targeting With for of year. our effort established for to XXXX UKONIQ on build pay of from that closely incredibly patients coming potential common The our grown years dividends B-cell future of platform, see and treatments touch pipeline impressed and with of we working so has work will beyond we launch we ublituximab and multiple launches and robust have CLL that will I RMS, both our including, with as commercial tremendously to and commercializing briefly our am intend that, commercial year novel we've team for the hard continued platform this which I in together footprint are the the and for of B-cell developing TG application diseases. excited everyone goal whether application and built off so, We our and in from occurring the BLA, won't Meeting, Annual on this ASH or late with Perhaps with our the multiple hot of referred FDA submission quarter and in our another ublituximab. discussing this or was past relapsing the to in sclerosis Multiple glycoengineered CMSC, off Since monoclonal that by Application thought Biologics is to news have look heels the MS. I Sclerosis available submitted I'd Consortium later. the late program. back call live forms hearing call this abstracts License accepted to anti-CDXX exciting for of They're forward Clinics patients September our minutes completed XX antibody to November for most filing. USFDA as we we this participation treat from of the they be team's kick
a XXXX. presented PDUFA at in would submission from This III target late date we Assuming our Conference additional September supported also the FDA. of I quarter, all and goes past the shared the which we and ULTIMATE trials, to II well, Phase anticipate data ECTRIMS BLA
months endpoint with these Meeting, of in MS with patients rate. assessment reminder, dose. importantly, community ublituximab the shared benefit starting special following relapse rate, noted ECTRIMS As endpoints data past, the protocol relapse their a the endpoint. highly treatment under additional historically annualized the on both offer a further secondary, as We data resulting we and additional post-hoc treat in in met with annualized demonstrates statistically tertiary believe to demonstrating additional treatment the initial potential every sometimes primary some FDA to levels infusion six also to of low significant as around trials one presented with primary and the ARR successful hour the ublituximab were with a the color even ublituximab studies reduction conducted referred RMS At
during KOLs the the of say, positive As of on I’d to our at overwhelmingly personally I best success tremendous listen ublituximab anyone to and feedback to the Furthermore, position leaders help a to us go we is ublituximab to encourage opportunity thoughts insights I event ECTRIMS recent a opinion hosted CMSC MS. key far. a had listen have the provided and also Annual was with data Meeting, provide for meet who reminder, and to the thus interested number this in presented website in their to recording to a the virtual event and TG Conference, and
program. UNITY-CLL the Phase III review let's Next,
who with well to candidates ublituximab, are trial Phase particular, be XXXX who commercialize as This received a who seeking statistically year available treatment. PDUFA for of significant care, the III approval UX In combination program, As with goal we patients a those which UX submitted recall, plus a those UNITY-CLL in standards conducted was These treated new about the you of to UKONIQ with UKONIQ, failed by CLL protocol the the for progression-free CLL. for FDA. survival and may treatment endpoint an currently refer who a of as and primary of patients to from were commercial around each the for for are options date of the achieved if alternative may approved. those achieved the received XX, supported new, not requesting patients patients CLL, a as and improvement compared many for its UX showed as of March excited good we and have you patients leverage BLA With applications are sNDA, need data an to patients combination and under we’ve this potential year, with chemo treatment special assessment built platform immunotherapy. current of
Now, let me turn to UKONIQ.
Journal agent As year, from who which patients accelerated a a with adult based This were or received and for approval subsequently UKONIQ single in of follicular this lines the zone UNITY-NHL at trial, anti-CDXX-based prior relapsed have systemic the granted relapsed least on with adult prior patients February one of received FDA refractory was the approval or the of least reminder, results as in lymphoma at regimen for the treatment of of marginal refractory lymphoma primarily have three published therapy. Oncology. Clinical who
introducing True have group. say challenges professionals Adam comments and with got to of of Waldman I've been of by and the working with my recently I pleased keep let what and an the performance team. I'll UKONIQ experience, the our Officer, launch, Chief details. Commercialization sales oncologists. impressive the our footprint establish to chance I most by meet brief to broader our Despite to provide the team hard COVID, posed very TG to in commercial person for vast community a our As
in our of follicular educate professionals prescribers also target mind CLL. treat and key to goals many clinicians has with team's treat One awareness possible, as with as that most of who are patients build and the current who the MZL been healthcare keeping
base and their and virtually potential will launch be of teams in success efforts, the the live which are bolster hard we single-agent practices and increasing MZL with base follicular providers engaged And community importantly, UKONIQ our UX to we CLL and and thousands for integral for all prescriber have if with UKONIQ believe So, building the prescriber Through approved. should experience our efforts grow. of UX. healthcare seeing continues uptick work
a expansion venetoclax. Starting with Lastly, discussing I minutes which spend pipeline will drive couple a hematology additional commercial of and of hope growth oncology wanted for outcome become future plus patients few platform. of our UX we programs, to better drivers and
at the from patients approximately treated a York, the Barr including results Center portion UX-plus the XX Phase patients this in Phase an among enrolling a I with which patients, a Conference, enrollment combination Paul III the of of this combination, presented Dr. this The XXX and Rochester, the rate. ven Cancer refractory As XXX% approximately complete triple overall Wilmot earlier XX% now reminder, Phase or II completed is Best valuable New with includes updated trial recently, response response regimen. of CLL. treatment-naive Most now triplet year. patients relapsed study evaluating this IWCLL ULTRA-V with
our a XX on be compared but should of in hosted stream data see our the Phase KOLs remainder investigational Importantly, you combinations, I safety clinical to for from with to website with forward as and activity IWCLL a next provide listen inhibitor peripheral approach disease providing XX% the the into also to our to in to as wanted with conference at year. by were appears review a steady and regimen. that Phase updates we residual potential novel a in are and show highlight the profile. important benefits this us We UX encourage cycle only see combinations and platform XXXX at undetectable residual we These believe of the I interested tolerable to look utility I patients, exciting who presented Also and directly backbone disease not given event a wrap again, that pleased of blood XX, BTK and and TG-XXXX, about to speak I of combination encouraging commercial TG monotherapy XX% those studies We UX. triple objectives we the to bone as the up, TG-XXXX combination note, Also, opportunities. continues IWCLL, what to as a achieved patients data patients are and and of of the undetectable XX in the upcoming feedback highly our achieved of these To II encouraging go minimal goals in minimal some virtual with triple XXXX. B-cell to marrow. the during quickly additional
look with to ublituximab of forward for hearing BLA submission patients we our FDA MS. treat regarding forms to First, from the relapsing
patients to for month of BLA/sNDA continue to which are XXXX. chronic in December, will target with the FDA ASH also on UX We goal We an with exciting having and March PDUFA looking have next to forward so date a live lymphocytic work there. a presence XX, leukemia, the Conference has plan
So exciting. that's be going to very
minutes just UX as live. go in for will abstracts we're doublet a so a combination potential therapy of A.M., We mentioned, as great a and be think As minutes that’s showcasing from as also value us combinations. a triple and now, conference the at the presenting will few of X:XX data backbone XX this utility
MS. in will and potential ublituximab or commercial refractory zone preparation future UKONIQ follicular in relapsing footprint UX continue commercialization forms relapsed for the launches we course, to on lymphoma and including in Of CLL of focus our of and and expand marginal
including the anti-CDXX, turn about, excited Chief We TG-XXXX, anti-PD-LX are Adam? but our a inhibitor bit plan to both call Adam the advance plus am that well, treatment and pipeline continuing as stage TG-XXXX, TG-XXXX, our our Phase antibody. venetoclax share highlights drive that, quite compounds CLL talking our and naive With over some triple been some our in continue relapsed/refractory evaluating the early III enrollment bispecific of Commercialization CD-XX early we Officer, I to earlier combination to to BTK our UX from candidates, including into ULTRA-V and our to we've Waldman trial efforts. to commercialization
